Cargando…
The Lantibiotic Peptide Labyrinthopeptin A1 Demonstrates Broad Anti-HIV and Anti-HSV Activity with Potential for Microbicidal Applications
Lantibiotics are peptides, produced by bacteria, that contain the noncanonical amino acid lanthionine and many of them exhibit antibacterial activities. The labyrinthopeptin A1 (LabyA1) is a prototype peptide of a novel class of carbacyclic lantibiotics. Here, we extensively evaluated its broad-spec...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665789/ https://www.ncbi.nlm.nih.gov/pubmed/23724015 http://dx.doi.org/10.1371/journal.pone.0064010 |
_version_ | 1782271302497730560 |
---|---|
author | Férir, Geoffrey Petrova, Mariya I. Andrei, Graciela Huskens, Dana Hoorelbeke, Bart Snoeck, Robert Vanderleyden, Jos Balzarini, Jan Bartoschek, Stefan Brönstrup, Mark Süssmuth, Roderich D. Schols, Dominique |
author_facet | Férir, Geoffrey Petrova, Mariya I. Andrei, Graciela Huskens, Dana Hoorelbeke, Bart Snoeck, Robert Vanderleyden, Jos Balzarini, Jan Bartoschek, Stefan Brönstrup, Mark Süssmuth, Roderich D. Schols, Dominique |
author_sort | Férir, Geoffrey |
collection | PubMed |
description | Lantibiotics are peptides, produced by bacteria, that contain the noncanonical amino acid lanthionine and many of them exhibit antibacterial activities. The labyrinthopeptin A1 (LabyA1) is a prototype peptide of a novel class of carbacyclic lantibiotics. Here, we extensively evaluated its broad-spectrum activity against HIV and HSV in vitro, studied its mechanism of action and evaluated potential microbicidal applications. LabyA1 exhibited a consistent and broad anti-HIV activity (EC(50)s: 0.70–3.3 µM) and anti-HSV activity (EC(50)s: 0.29–2.8 µM) in cell cultures. LabyA1 also inhibited viral cell-cell transmission between persistently HIV-infected T cells and uninfected CD4(+) T cells (EC(50)∶2.5 µM) and inhibited the transmission of HIV captured by DC-SIGN(+)-cells to uninfected CD4(+) T cells (EC(50)∶4.1 µM). Time-of-drug addition studies revealed that LabyA1 acts as an entry inhibitor against HIV and HSV. Cellular and virus binding studies combined with SPR/FLIPR technology showed that LabyA1 interacted with the HIV envelope protein gp120, but not with the HIV cellular receptors. LabyA1 also demonstrated additive to synergistic effects in its anti-HIV-1 and anti-HSV-2 activity with anti(retro)viral drugs in dual combinations such as tenofovir, acyclovir, saquinavir, raltegravir and enfuvirtide. LabyA1 can be considered as a novel lead peptide as it had profound antiviral activity against HIV and HSV. Pre-treatment of PBMCs with LabyA1 neither increased the expression of the activation markers CD69 and CD25, nor enhanced HIV replication, nor significantly induced various inflammatory cytokines/chemokines. LabyA1 also did not affect the growth of vaginal Lactobacilli populations. Based on the lack of toxicity on the vaginal Lactobacillus strains and its synergistic/additive profile in combination with clinically approved anti(retro)virals, it deserves further attention as a potential microbicide candidate in the prevention of sexual transmitted diseases. |
format | Online Article Text |
id | pubmed-3665789 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-36657892013-05-30 The Lantibiotic Peptide Labyrinthopeptin A1 Demonstrates Broad Anti-HIV and Anti-HSV Activity with Potential for Microbicidal Applications Férir, Geoffrey Petrova, Mariya I. Andrei, Graciela Huskens, Dana Hoorelbeke, Bart Snoeck, Robert Vanderleyden, Jos Balzarini, Jan Bartoschek, Stefan Brönstrup, Mark Süssmuth, Roderich D. Schols, Dominique PLoS One Research Article Lantibiotics are peptides, produced by bacteria, that contain the noncanonical amino acid lanthionine and many of them exhibit antibacterial activities. The labyrinthopeptin A1 (LabyA1) is a prototype peptide of a novel class of carbacyclic lantibiotics. Here, we extensively evaluated its broad-spectrum activity against HIV and HSV in vitro, studied its mechanism of action and evaluated potential microbicidal applications. LabyA1 exhibited a consistent and broad anti-HIV activity (EC(50)s: 0.70–3.3 µM) and anti-HSV activity (EC(50)s: 0.29–2.8 µM) in cell cultures. LabyA1 also inhibited viral cell-cell transmission between persistently HIV-infected T cells and uninfected CD4(+) T cells (EC(50)∶2.5 µM) and inhibited the transmission of HIV captured by DC-SIGN(+)-cells to uninfected CD4(+) T cells (EC(50)∶4.1 µM). Time-of-drug addition studies revealed that LabyA1 acts as an entry inhibitor against HIV and HSV. Cellular and virus binding studies combined with SPR/FLIPR technology showed that LabyA1 interacted with the HIV envelope protein gp120, but not with the HIV cellular receptors. LabyA1 also demonstrated additive to synergistic effects in its anti-HIV-1 and anti-HSV-2 activity with anti(retro)viral drugs in dual combinations such as tenofovir, acyclovir, saquinavir, raltegravir and enfuvirtide. LabyA1 can be considered as a novel lead peptide as it had profound antiviral activity against HIV and HSV. Pre-treatment of PBMCs with LabyA1 neither increased the expression of the activation markers CD69 and CD25, nor enhanced HIV replication, nor significantly induced various inflammatory cytokines/chemokines. LabyA1 also did not affect the growth of vaginal Lactobacilli populations. Based on the lack of toxicity on the vaginal Lactobacillus strains and its synergistic/additive profile in combination with clinically approved anti(retro)virals, it deserves further attention as a potential microbicide candidate in the prevention of sexual transmitted diseases. Public Library of Science 2013-05-28 /pmc/articles/PMC3665789/ /pubmed/23724015 http://dx.doi.org/10.1371/journal.pone.0064010 Text en © 2013 Férir et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Férir, Geoffrey Petrova, Mariya I. Andrei, Graciela Huskens, Dana Hoorelbeke, Bart Snoeck, Robert Vanderleyden, Jos Balzarini, Jan Bartoschek, Stefan Brönstrup, Mark Süssmuth, Roderich D. Schols, Dominique The Lantibiotic Peptide Labyrinthopeptin A1 Demonstrates Broad Anti-HIV and Anti-HSV Activity with Potential for Microbicidal Applications |
title | The Lantibiotic Peptide Labyrinthopeptin A1 Demonstrates Broad Anti-HIV and Anti-HSV Activity with Potential for Microbicidal Applications |
title_full | The Lantibiotic Peptide Labyrinthopeptin A1 Demonstrates Broad Anti-HIV and Anti-HSV Activity with Potential for Microbicidal Applications |
title_fullStr | The Lantibiotic Peptide Labyrinthopeptin A1 Demonstrates Broad Anti-HIV and Anti-HSV Activity with Potential for Microbicidal Applications |
title_full_unstemmed | The Lantibiotic Peptide Labyrinthopeptin A1 Demonstrates Broad Anti-HIV and Anti-HSV Activity with Potential for Microbicidal Applications |
title_short | The Lantibiotic Peptide Labyrinthopeptin A1 Demonstrates Broad Anti-HIV and Anti-HSV Activity with Potential for Microbicidal Applications |
title_sort | lantibiotic peptide labyrinthopeptin a1 demonstrates broad anti-hiv and anti-hsv activity with potential for microbicidal applications |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665789/ https://www.ncbi.nlm.nih.gov/pubmed/23724015 http://dx.doi.org/10.1371/journal.pone.0064010 |
work_keys_str_mv | AT ferirgeoffrey thelantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications AT petrovamariyai thelantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications AT andreigraciela thelantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications AT huskensdana thelantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications AT hoorelbekebart thelantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications AT snoeckrobert thelantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications AT vanderleydenjos thelantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications AT balzarinijan thelantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications AT bartoschekstefan thelantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications AT bronstrupmark thelantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications AT sussmuthroderichd thelantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications AT scholsdominique thelantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications AT ferirgeoffrey lantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications AT petrovamariyai lantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications AT andreigraciela lantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications AT huskensdana lantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications AT hoorelbekebart lantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications AT snoeckrobert lantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications AT vanderleydenjos lantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications AT balzarinijan lantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications AT bartoschekstefan lantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications AT bronstrupmark lantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications AT sussmuthroderichd lantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications AT scholsdominique lantibioticpeptidelabyrinthopeptina1demonstratesbroadantihivandantihsvactivitywithpotentialformicrobicidalapplications |